Arcadia Investment Management Corp MI Trims Stock Position in Danaher Corporation $DHR

Arcadia Investment Management Corp MI reduced its stake in Danaher Corporation (NYSE:DHR) by 29.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,956 shares of the conglomerate’s stock after selling 3,300 shares during the quarter. Arcadia Investment Management Corp MI’s holdings in Danaher were worth $1,572,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Red Tortoise LLC raised its position in Danaher by 175.0% during the 2nd quarter. Red Tortoise LLC now owns 154 shares of the conglomerate’s stock worth $30,000 after buying an additional 98 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of Danaher in the second quarter valued at about $40,000. Costello Asset Management INC acquired a new position in shares of Danaher during the first quarter worth about $41,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in Danaher by 53.8% during the first quarter. Mowery & Schoenfeld Wealth Management LLC now owns 203 shares of the conglomerate’s stock worth $42,000 after purchasing an additional 71 shares in the last quarter. Finally, Strengthening Families & Communities LLC lifted its position in Danaher by 81.4% in the first quarter. Strengthening Families & Communities LLC now owns 254 shares of the conglomerate’s stock valued at $52,000 after purchasing an additional 114 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Bank of America reduced their price target on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. JPMorgan Chase & Co. lifted their price target on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday, September 2nd. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 target price (down previously from $245.00) on shares of Danaher in a report on Wednesday, October 8th. Eighteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.39.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 5,174 shares of Danaher stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the transaction, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This represents a 66.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 29,728 shares of company stock valued at $6,448,990. 11.20% of the stock is currently owned by company insiders.

Danaher Stock Up 0.0%

DHR stock opened at $221.25 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The company has a 50 day moving average price of $205.63 and a two-hundred day moving average price of $201.09. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a market capitalization of $156.28 billion, a P/E ratio of 45.62, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the business posted $1.71 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. As a group, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.